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ABSTRACT
Alzheimer’s disease (AD) is themost prevalent age-related neurodegenerative disorder and a leading
cause of dementia. Current treatment fails to modify underlying disease pathologies and very little
progress has been made to develop effective drug treatments. Cellular therapies impact disease by
multiple mechanisms, providing increased efficacy compared with traditional single-target ap-
proaches. In amyotrophic lateral sclerosis, we have shown that transplanted spinal neural stem cells
(NSCs) integrate into the spinal cord, form synapseswith the host, improve inflammation, and reduce
disease-associated pathologies. Our current goal is to develop a similar “best in class” cellular therapy
for AD. Here, we characterize a novel human cortex-derived NSC line modified to express insulin-like
growth factor-I (IGF-I), HK532-IGF-I. Because IGF-I promotes neurogenesis and synaptogenesis in vivo,
this enhancedNSC lineoffersadditional environmental enrichment, enhancedneuroprotection, anda
multifaceted approach to treating complex AD pathologies.We show that autocrine IGF-I production
does not impact the cell secretome or normal cellular functions, including proliferation, migration,
or maintenance of progenitor status. However, HK532-IGF-I cells preferentially differentiate into
gamma-aminobutyric acid-ergic neurons, a subtype dysregulated in AD; produce increased vascular
endothelial growth factor levels; and display an increased neuroprotective capacity in vitro. We also
demonstrate that HK532-IGF-I cells survive peri-hippocampal transplantation in a murine AD model
and exhibit long-term persistence in targeted brain areas. In conclusion, we believe that harnessing
the benefits of cellular and IGF-I therapies together will provide the optimal therapeutic benefit to
patients, and our findings support further preclinical development of HK532-IGF-I cells into a
disease-modifying intervention for AD. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:379–391
SIGNIFICANCE
There is no cure for Alzheimer’s disease (AD) and nomeans of prevention. Current drug treatments tem-
porarily slow dementia symptoms but ultimately fail to alter disease course. Given the prevalence of AD
and an increasingly aging population, alternative therapeutic strategies are necessary. Cellular therapies
impact disease by multiple mechanisms, providing increased efficacy compared with traditional, single-
targetdrugdiscoveryapproaches.Thisstudydescribesanovelenhancedhumanstemcell linethatproduces
increased amounts of growth factors beneficial to the disease environment. Findings support further devel-
opment into a potentially safe and clinically translatable cellular therapy for patients with AD.
INTRODUCTION
Alzheimer’s disease (AD) is a progressive and ir-
reversible neurodegenerative disorder, affect-
ing an estimated 5.3 million people in the U.S.
[1]. With increasingly aging populations and an
unprecedented number of cases, AD is a signifi-
cant public health concern; health-care costs
exceeded $200 billion in 2013 alone [1]. Patients
typically exhibit progressive cognitive decline,
including memory loss and abnormalities in
learning and behaviors, and the disease is ulti-
mately fatal. Although the exact etiology and
pathogenesis remain unclear, disease patholo-
gies include amyloid b (Ab) plaques, hyperphos-
phorylated tau protein and neurofibrillary tangles
[2–4], neuroinflammation, synapse loss, andmas-
sive neuronal damage across multiple regions
[5, 6]. Current U.S. Food and Drug Administra-
tion (FDA)-approved drug treatments temporarily
aDepartment of Neurology,
bDepartment of







Correspondence: Eva L. Feldman,
M.D., Ph.D., 5017 AAT-BSRB, 109




ReceivedMay 12, 2015; accepted
for publication November 19,






STEM CELLS TRANSLATIONAL MEDICINE 2016;5:379–391 www.StemCellsTM.com ©AlphaMed Press 2016
TISSUE ENGINEERING AND REGENERATIVE MEDICINE
slow dementia symptoms but fail to alter the course of the disease
[7, 8]. Given the complexity of AD and the numerous pathways in-
volved, it is increasingly likely that multifaceted approaches are
necessary.
Cell-based therapies represent an entirely new approach to
standard drug discovery and development pipelines because
they impact disease by multiple mechanisms. In addition to
tissue replacement, cellular therapy supports environmental
enrichment through targeted and sustained delivery of pa-
racrine factors [9]. A significant pathological finding in pa-
tients with AD is degeneration of neurons in areas connected
to the cerebral cortex and hippocampus, particularly neurons
in the basal forebrain and cholinergic neurons [10, 11]. These
memory and learning centers of the brain are attractive targets
for cellular therapeutics because impacting degeneration in
these areas could potentially improve cognitive deficits in AD.
Transplantation of neural stem cells (NSCs) to the hippocam-
pal area improves cognition, neuronal survival, and synapse
function in transgenic ADmice,mediated byNSC-derived neuro-
trophin activity [12–16]. Mesenchymal stem cells are also neu-
roprotective in AD through their ability to modulate cytokine
levels and inflammation in the brain [17–19]. Many of these
studies suggest that efficacy is enhanced when coupled with
the delivery of trophic factors that can improve neurological dis-
orders [20–22]. Combination approaches, in which stem cells
are engineered to produce additional growth factors, provide in-
creased cellular and trophic support [23–26]. Insulin-like growth
factor-I (IGF-I) is an essential trophic factor for neuronal devel-
opment andnormal function [27, 28]. Signaling through the IGF-I
receptor (IGF-IR) stimulates proliferation and differentiation
[29–32], and exerts neuroprotective effects via activation of
twomajor signaling pathways: themitogen-activated protein ki-
nase (MAPK) pathway and the phosphatidylinositol 3-kinase/
Akt pathway [33, 34]. These neuroprotective effects are seen
in multiple cell types, including cholinergic and hippocam-
pal neurons [33, 35–37]. In vivo, IGF-I is antiapoptotic and
anti-inflammatory, and promotes synapse formation [30, 31,
38–45]. Reduced IGF-I levels are associated with cognitive de-
cline, and, conversely, increased IGF-I in the hippocampus pre-
vents cognitive deficits [35, 46]. Thus, the neuroprotective
capacity of IGF-I in degenerative disease and the correlation be-
tween decreased IGF-I and cognitive defects support the use
of IGF-I in AD treatment approaches.
Our goal is to identify and develop amechanism-based, “best
in class” cellular therapy for patients with AD, andwe anticipate
that harnessing the benefits of cellular and growth factor ther-
apies together will provide the required therapeutic option.
In this study, we established the HK532-IGF-I cell line by modi-
fying human cortical NSCs to produce increased IGF-I. We first
characterized the effects of IGF-I production on normal NSC
behaviors, including proliferation, migration, maintenance of
progenitor status, and initial differentiation into selective neu-
ronal subtypes. Next, we evaluated the therapeutic potential and
neuroprotective capacity ofHK532-IGF-I in an in vitromodel of AD-
associated Ab(1-42) toxicity. Importantly, we demonstrate in vivo
engraftment and survival of HK532-IGF-I cells in the brain after
peri-hippocampal transplantation in amousemodel of AD. Collec-
tively, our findings strongly support further large-scale preclinical
studies using transgenic models to determine the therapeutic
efficacy of HK532-IGF-I cells as a disease-modifying treatment
option for AD.
MATERIALS AND METHODS
HK532 Preparation, Culture, and Differentiation
The human cortical NSC lines (NSI-HK532 and NSI-HK532.UbC-
IGF-I) were provided by Neuralstem, Inc. (Germantown, MD,
http://www.neuralstem.com). Briefly, HK532 were prepared
from cortical tissue obtained from a single 8-week-old human fe-
tus following an elective abortion, as previously described [47,
48]. Thematerial was donated to Neuralstem, Inc. with informed
consent in amanner compliant with guidelines of the National In-
stitutes of Health and the FDA, and according to guidelines that
were reviewed and approved by an outside independent review
board.
Cortical NSCs were conditionally immortalized using a retro-
virus vector containing an immortalizing gene comprising human
cMYC cDNA fused at the 39 end with a cDNA fragment coding for
the c-terminal ligand binding domain of human estrogen recep-
tor, and the neomycin-resistance gene. Cells were selected for
neomycin resistance, propagated as a single cell line (HK532),
and transduced with a replication‐defective recombinant lenti-
viral vector to induce expression of human IGF-I, driven by the
human ubiquitin C (UbC) promoter. Resulting cells were prop-
agated as a single cell line without further selection (HK532.
UbC-IGF-I).
HK532 and HK532-IGF-I cell lines were routinely cultured in
Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Corning,
Manassas, VA, http://www.cellgro.com) supplemented with
10 ng/ml fibroblast growth factor (FGF) on poly-D-lysine (PDL),
100mg/ml, and fibronectin (FN), 25mg/ml, coated surfaces (Milli-
pore, Billerica,MA, http://www.emdmillipore.com), according to
our previously established NSC culture protocols [41, 42]. For dif-
ferentiation, cells were cultured without FGF in differentiation
medium (DMEM supplemented with 4 mM L-glutamine, 20 mM
L-alanine, 6 mM L-asparagine, 67 mM L-proline, 250 nM vitamin
B12, 25 mg/l insulin, 100 mg/l transferrin, 20 nM progesterone,
100mMputrescine, and 30 nM sodium selenite), with 50%media
changes every 2 days. Differentiated cell data are presented as
days postdifferentiation (i.e., undifferentiated [D0], day 1 [D1],
and so forth).
Growth Factor Production and Signaling
IGF-I expressionand signalingweredeterminedbyenzyme-linked
immunosorbent (ELISA) and Western blotting, as previously de-
scribed [33, 49]. To confirm IGF-I production and determine the
NSC growth factor profile, conditioned medium was collected
fromD0, D3, andD7 cells, concentrated 10‐fold to 1ml using Cen-
tricon filters (3-kDa cutoff) (Millipore), and run onhuman-specific
ELISAs for IGF-I (Assay Designs; Enzo Life Sciences Inc., Farming-
dale, NY, http://www.enzolifesciences.com), brain-derived neu-
rotrophic factor (BDNF), glial cell line-derived neurotrophic
factor (GDNF), and vascular endothelial growth factor (VEGF)
(all from Raybiotech, Norcross, GA, http://www.raybiotech.
com), according to the manufacturer’s instructions. For IGF-I sig-
naling analysis, cells were cultured in differentiation medium
without insulin for 4 hours before the addition of select inhibi-
tors for 1 hour and subsequent addition of exogenous IGF-I
(20 nM) for 30 minutes. Inhibitors included the Akt pathway in-
hibitor LY294002 (LY), 20 mM (Sigma-Aldrich, St. Louis, MO,
https://www.sigmaaldrich.com), the MAPK inhibitor U0126 (U),
20 mM, (Millipore, La Jolla, CA, https://www.emdmillipore.com)
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or the IGF-IR inhibitor NVPAEW541 (NVP), 1mM (Sigma-Aldrich).
For Western blot analysis, total cell protein was extracted in ice-
cold radioimmunoprecipitation assay buffer (20 mM Tris; pH 7.4;
150mMNaCl; 1mMEDTA; 0.1% SDS; 1mMNa deoxycholate; 1%
Triton X-100; 0.1 trypsin units/l aprotinin, 10 mg/ml leupeptin,
and 50mg/ml phenylmethylsulfonyl fluoride), protein concentra-
tion was determined, and samples were electrophoresed on an
sodium dodecyl sulfate polyacrylamide gel electrophoresis gel
and transferred to nitrocellulose. Primary antibodies included
phospho-IGF-IR (pIGF-IR), IGF-IRb (Tyr1135/1136), phospho-Akt
(Ser473) (pAkt), Akt, phospho-ERK (pERK), ERK (all from Cell
Signaling Technology, Inc., Danvers, MA, http://www.cellsignal.
com) and (Millipore, Temecula, CA, http://www.emdmillipore.
com). After overnight primary antibody incubation at 4°C, mem-
branes were incubated with the appropriate secondary antibody
conjugated to horseradish peroxidase (Cell Signaling Technology)
for 1 hour at 22°C, developed with a chemiluminescent substrate
(SuperSignal West Pico; Thermo Fisher Scientific, Hampton, NH,
https://www.thermofisher.com), and exposed to Kodak BioMax
XAR film (Sigma-Aldrich).
Cellular Migration
Undifferentiated HK532 and HK532-IGF-I cells were added to mi-
gration inserts following overnight storage at 4°C (13 106 cells/
ml or 33 106 cells per vial), or were alternatively cultured on six-
well plates and moved to inserts on D7 of differentiation. NSDM
plus 10% fetal bovine serum was added below the inserts. After
24 hours, cells that hadmigrated through the insert were stained
using theQCM24-wellColorimetricCellMigrationAssay (Millipore).
Migration was quantified using a standard LabSystems Fluoroskan
Ascent FL microplate reader (Thermo Fisher Scientific) at 530 and
590 nm.
Cellular Proliferation and Differentiation
Cellular proliferation and differentiation were assessed using
standard immunocytochemistry (ICC) protocols [50, 51]. Briefly,
HK532 and HK532-IGF-I cells were cultured on PDL/FN-coated
glass coverslips. Proliferation was measured as previously de-
scribed [51] at D0, D3, and D7 by incubating cells with 10 mM
59-ethynyl-2’-deoxyuridine (EdU) for 2 hours before fixation
and processing following the manufacturers’ protocols for the
Click-It EdU kit (Thermo Fisher Scientific). EdU incorporation
was measured by quantification of fluorescent images captured
using an Olympus BX-51 microscope (Olympus Corp., Center Val-
ley, PA, http://www.olympusamerica.com). Approximately 2.53
103 to 2.73 103 cells were counted per proliferation experiment
for all samples (n = 3).
To assess differentiation, cellswere fixedwith 4%paraformal-
dehyde (PFA), permeabilized with 0.1% Triton/phosphate-
buffered saline (PBS), and blocked in 5% normal donkey serum
per 0.1% Triton/PBS. Next, Ki67 (Novus Biologicals, Littleton,
CO, http://www.novusbio.com), TUJ1 (Neuromics, Edina, MN,
http://www.neuromics.com), Nestin (Millipore), glutamic acid
decarboxylase 65/67 (GAD65/67) (Millipore), vesicular glutamate
transporter 2 (VGLUT2) (Millipore), or IGF-IRb (1:500; Sigma-
Aldrich) primary antibodies were incubated at 1:1,000, unless
otherwise indicated, overnight at 4°C. Cells were then incubated
in Cy3, Cy5, or fluorescein isothiocyanate-conjugated secondary
antibodies (Jackson ImmunoResearch, Westgrove, PA, https://
www.jacksonimmuno.com) and mounted on glass slides using
ProLongGoldantifadewith49,6-diamidino-2-phenylindole (DAPI)
(Thermo Fisher Scientific). Images were captured using an Olym-
pus BX-51 microscope (Olympus Corp.) and approximately 2.53
103 to 2.7 3 103 cells were counted per differentiation experi-
ment for all samples (n = 3).
Maintenanceofprogenitor status andaxonal outgrowthwere
assessed using our previously established neural index measure-
ment [41, 42]. Briefly, cells were cultured on PDL/FN-coated glass
coverslips for the first 7 days of differentiation and immunola-
beled atD0, D3, andD7withNestin to identify neural progenitors,
or with TUJ1 to observe primary neuronal processes. More than
2.5 3 103 cells were counted per experiment for all Nestin-
labeled samples (n = 3). To calculate neural index, the number
of neurons and neurite lengthweremeasured in TUJ1-labeled im-
agesusingMetaMorph (MolecularDevices, Sunnyvale, CA,http://
www.moleculardevices.com). Data are presented as neurite area
per cell (mm2 per cell) and a total of six images per conditionwere
counted, representing approximately 7.5 3 103 DAPI-labeled
cells (n = 3).
Primary Cortical Neuron Preparation and Assessment
of Neuroprotection
Primary cortical neurons (CNs)were isolatedaccording toourpre-
viously published protocol [52]. Briefly, E15 Sprague-Dawley rat
embryos were collected, membranes were removed, and the tis-
suewas chopped into2- to3-mmpieces. Cellsweredissociatedby
incubating the tissue in 0.5% trypsin/EDTA for 10minutes at 37°C
followed by trituration with a serum-coated glass pipette for
1 minute. The resulting cell suspension was applied to poly-L-
lysine-coated glass coverslips (100 mg/ml) in growth medium,
which comprised Neurobasal Medium (Thermo Fisher Scientific)
supplemented with 2.5 mg/ml albumin, 2.5 mg/ml catalase, 2.5
mg/ml superoxide dismutase, 0.01 mg/ml transferrin, 15 mg/ml
galactose, 6.3 ng/ml progesterone, 16 mg/ml putrescine,
4 ng/ml selenium, 3 ng/ml b-estradiol, 4 ng/ml hydrocortisone,
13 penicillin/streptomycin/neomycin, and 13 B-27 additives
(Thermo Fisher Scientific). To examine cell susceptibility to the
toxic AD microenvironment, CN, HK532, and HK532-IGF-I cells
(undifferentiated and D7 differentiated) were treated with
10 mM Ab(1-42) (rPeptide, Bogart, GA, https://www.rpeptide.
com) for approximately 72 hours. To assess NSC-mediated neuro-
protective effects, primary CNs were cocultured with PDL/FN-
coated, 3-mm-pore transwell inserts (Corning) containing D7
HK532 or HK532-IGF-I. After 24 hours in NSDM, cocultures were
starved overnight in treatment medium and subjected to 10 mM
Ab for 72 hours. The contribution of paracrine IGF‐I production to
protective capacity was assessed by adding 1mMNVP 2hours be-
fore Ab. Cellular injury was determined by counting the percent-
age of cleaved caspase-3 (CC3)-positive cells following ICC with a
CC3 antibody (1:1,000; Cell Signaling Technology). Approximately
3.0 3 103 to 3.5 3 103 cells were counted per neuroprotection
experiment for all samples (n = 3).
In Vivo Transplantation
All procedures were in compliance with protocols approved by
the University of Michigan (U-M) University Committee on Use
and Care of Animals and detailed under protocol 3917. Daily
monitoringandmaintenanceofmicewasprovidedbytheU-MUnit
for Laboratory Animal Medicine. B6C3-Tg(APPswe/PSEN1DE9)
85Dbo/J (APP/PS1; n = 5) and wild-type (WT) B6C3F1/J (n = 8)
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mice were obtained from the Jackson Laboratory (Bar Harbor,
ME, https://www.jax.org). At 11 weeks of age, mice received
subcutaneous tacrolimus pellets (FK-506; Neuralstem, Inc.),
which were continued for the study duration. At 12 weeks of
age, mice were anesthetized with isofluorane and placed in
a standard stereotactic frame (Stoelting Co., Wood Dale, IL,
http://www.stoeltingco.com). HK532-IGF-I cell suspensions
were administered by bilateral injections into the fimbria for-
nix of the hippocampus at three sites using the following co-
ordinates from the bregma (axial, sagittal, and coronal planes):
20.82, 0.75, 2.5;21.46, 2.3, 2.9; and21.94, 2.8, 2.9 mm, respec-
tively, injecting a total cell number of 180,000 per animal. Two and
10weeks after cell transplantation, animals were anesthetized and
perfusedwith ice-cold saline, and their brains were dissected along
the interhemispheric boundary and postfixed in 4% PFA overnight,
followed by cryoprotection in 30% sucrose for immunohistochem-
istry (IHC).
Ten hippocampal sections (14 mm) per animal were selected
for IHC to detect grafted cells and verify accurate targeting to the
fimbria fornix. Sections were rehydrated in PBS, permeabilized in
0.5%TritonX-100 inPBS for20minutes, andblocked in5%donkey
serum in 0.1% Triton X-100 in 13 PBS for 30minutes. Primary an-
tibodies for Doublecortin (DCX) and human nuclei (HuNu) (both
fromMillipore) were diluted 1:200 in blocking solution and incu-
bated with sections overnight at 4°C. After primary antibody
incubation, sections were washed three times in PBS and incu-
bated for 1 hour with fluorescent-conjugated secondary anti-
bodies raised in donkey (Alexa 488 and Alexa 594; 1:500;
Thermo Fisher Scientific). Slides were mounted with glass
coverslips using ProLong Gold antifade mounting medium con-
taining DAPI nuclear stain (Thermo Fisher Scientific), and fluo-
rescent images were captured using a Leica SP2 confocal
microscope (Leica Microsystems, Buffalo Grove, IL, http://
www.leica-microsystems.com).
Statistical Analyses
All data are presented as mean 6 SD (n = 3), or as representa-
tive images of three independent experiments. Statistical signif-
icance was determined by paired t tests or one‐way analysis of
variance followed by Tukey’s multiple comparison test using
GraphPad Prism (GraphPad Software Inc., La Jolla, CA, http://
www.graphpad.com). Values of p, .05 were considered statisti-
cally significant.
RESULTS
Growth Factor Production and Signaling
To enhance the efficacy of human cortex-derived HK532 cells as
a cellular therapeutic, we generated the HK532-IGF-I cell line
that stably produces IGF-I. ELISA analysis of conditioned me-
dium demonstrated that parental HK532 cells produced very
low to undetectable basal levels of IGF-I, whereas HK532-IGF-
I cells produced 3–5 ng/ml of IGF-I between D0 and D7, approxi-
matelya50-fold increase(Fig.1A). Thus,HK532-IGF-I cellsproduced
appreciable levels of IGF-I that were maintained throughout
early differentiation, confirming robust and stable IGF-I expres-
sion. We also assessed the growth factor profile of the two cell
lines by ELISA analysis on conditioned medium from undiffer-
entiated and differentiated cells (Fig. 1D). BDNF and GDNF
production did not considerably differ between cell lines
and time points, whereas VEGF productionwas significantly in-
creased in undifferentiated HK532-IGF-I relative to parental
cells.
Since NSCs respond to IGF‐I signaling [41, 42, 53], we ex-
amined how growth factor receptor level and activation are
regulated by autocrine IGF‐I expression. By ICC, IGF‐IR expres-
sion was observed along the cell surface of both parental
HK532 and HK532-IGF-I cells at D7 (Fig. 1B, 1C). Western blot
analysis confirmed this expression, which was significantly
increased after differentiation in both cell lines (Fig. 1E).
Although slightly reduced IGF-IR expression levels were ob-
served in HK532-IGF-I cells relative to HK532 cells at D0 and
D7, IGF-IR phosphorylation and signaling activation did not
significantly differ between cell lines, and addition of exoge-
nous IGF-I resulted in increased phosphorylation of the recep-
tor (Fig. 1E) and was significantly more pronounced after
differentiation.
We next assessed phosphorylation and downstream acti-
vation of MAPK/Akt pathways in HK532 and HK532-IGF-I cells
(Fig. 1E). While basal MAPK signaling was present at D0 and D7,
therewere no significant differences between cell lines, and IGF-I
stimulation only increased signaling after differentiation. Basal
Akt signaling, however, was significantly increased in D0
HK532-IGF-I cells and in both cell lines after differentiation. Addi-
tion of exogenous IGF-I promoted a robust increase in Akt in
HK532 cells after differentiation,whereas very little Akt activation
was observed following IGF-I stimulation in HK532-IGF-I. These
data demonstrate a decreased responsiveness of HK532-IGF-I
to exogenous IGF-I relative to parental cells. Notably, inhibition
of MAPK signaling increased Akt phosphorylation and inhibition
of Akt signaling resulted in the reverse observation, suggesting
that these pathways are capable of compensatory signaling. Inhi-
bition of IGF-IR signaling using the receptor antagonist NVP did
not affect MAPK signaling but significantly depleted activa-
tion of IGF-IR and Akt to below basal levels in both cell lines
(Fig. 1E). Together, these data demonstrate that HK532-IGF-I
cells exhibit normal IGF-IR andMAPK/Akt signaling profiles, albeit
with an expected diminished responsiveness to exogenous IGF-I
stimulation.
IGF-I Expression Does Not Alter HK532 Proliferation
or Migration
IGF‐I can impact various cell behaviors, such as proliferation and
migration [29, 32]; therefore, we next used EdU incorporation
to assess the effect of IGF-I on HK532 and HK532-IGF-I cell prolif-
eration. Approximately 36% and 33% of untreated D0 HK532 and
HK532-IGF-I cells were EdU positive, respectively (Fig. 2A–2E). At
D3, 6% and 9% of HK532 and HK532-IGF-I were EdU-positive, re-
spectively, and by D7, less than 3% of either cell line was EdU
positive. Thus, no differences in the proliferation profiles were
observed at D0, D3, or D7, and both lines exhibited minimal
proliferation at D7. These data demonstrate that IGF-I does not
promote or maintain proliferation during the initial stages of dif-
ferentiation. The effect of IGF-I on HK532 and HK532-IGF-I migra-
tionwas also assessed at D0 andD7. Comparablemigration levels
were observed for HK532 and HK532-IGF-I at both time points
tested (Fig. 2F, 2G). Furthermore, when additional IGF-I was
added below transwell inserts, no change was detected (data
not shown). Thus, induced IGF-I expression exertednodiscernible
effects on NSC migration.
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Figure 1. IGF-I production, growth factor profile, and signaling in HK532 and HK532-IGF-I cells. (A): Production of IGF-I in HK532 and HK532-IGF-I
throughout early differentiation. Representative immunocytochemistry images of D7 HK532 (B) and HK532-IGF-I (C) cells labeled with 49,6-
diamidino-2-phenylindole (DAPI) (blue) and IGF-IR (green). (D):BDNF, GDNF, andVEGFproduction in undifferentiatedHK532 andHK532-IGF-I cells
(D0)andthroughoutearlydifferentiation (D3,D5, andD7).Growthfactorproduction isexpressedas foldchange relative toparentalHK532cells. (E):
Western blot analysis of IGF-I signaling in undifferentiated anddifferentiated (D7) HK532 andHK532-IGF-I cells. Cells were treatedwith an inhibitor
panel of LY, U, or NVP for 1 hour, followed by IGF-I treatment for 30minutes. All blots were probedwith pIGF-IR, IGF-IR, pERK, ERK, pAKT, andAKT.
b-actin was used as a loading control. Data are presented as mean + SD or are representative images of at least three independent experiments.
Scale bar = 50mm.p, p, .05. Abbreviations: BDNF, brain-derived neurotrophic factor; D0 (D3,D7), day 0 (day 3, day 7); GDNF, glial cell line-derived
neurotrophic factor; IGF-I, insulin-like growth factor-I; IGF-IR, insulin-like growth factor-I receptor; LY, LY294002; NVP, NVPAEW541; U, U0126;
VEGF, vascular endothelial growth factor.
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IGF-I-Expressing HK532 Cells Retain Neural
Differentiation Capacity
We previously reported that both exogenous and autocrine
IGF‐I-enhanced spinal NSC neural differentiation [41, 42], and
so we next examined the impact of IGF-I on the maintenance
of HK532 progenitor status and axonal outgrowth. Approxi-
mately 92% and 90% of D0 HK532 and HK532-IGF-I cells were
Nestin positive, respectively, indicating that IGF-I expression
did not affect the maintenance of progenitor status. IGF-I pro-
motes axonal outgrowth [50, 54, 55], so we also assessed the
effect of IGF-I on neurite outgrowth, using our established neu-
ral index approach as an early indicator of neuronal differenti-
ation [41, 42, 56]. For both HK532 and HK532-IGF-I cells, the
neural index increased between D0 and D7 as the cells differen-
tiated, but we did not observe any significant differences be-
tween the cell lines at any time point tested (Fig. 3F). These
Figure 3. Induced insulin-like growth factor-I (IGF-I) expression does
not affect maintenance of progenitor status or neurite outgrowth
during differentiation. (A, B): Representative immunocytochemis-
try (ICC) image of D0 HK532 and HK532-IGF-I cells labeled with
49,6-diamidino-2-phenylindole (DAPI) (blue) and Nestin (red). (C):
Quantification of Nestin-positive D0 HK532 and HK532-IGF-I cells.
(D, E): Representative ICC image of D7 HK532 and HK532-IGF-I cells
labeled with DAPI (blue) and TUJ1 (red). (F): Quantification of the
neural index measurement (mm2 per cell). Data are presented as
mean + SD or are representative images of at least three indepen-













Figure 2. Induced insulin-like growth factor-I (IGF-I) expression does
not affect HK532 cell proliferation and migration. (A): Quantification
of the percent of EdU-positive cells at D0, D3, and D7 in HK532 and
HK532-IGF-I cultures. (B–E): Representative immunocytochemistry
images of D0 and D7 HK532 and HK532-IGF-I cells labeled with
49,6-diamidino-2-phenylindole (DAPI) (blue) and EdU (green). (F–G):
Quantification of absorbance ofmigrated HK532 and HK532-IGF-I cells
at D0 and D7. Data are presented as mean + SD or are representative
images of at least three independent experiments. Scale bar = 200mm.
p, p , .05. Abbreviations: D0 (D3, D7), day 0 (day 3, day 7); EdU,
59-ethynyl-2’-deoxyuridine.
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data demonstrate that IGF-I does not affect initial HK532 cell
differentiation.
GABAergic But Not Glutamatergic Phenotypes Are
Increased in HK532-IGF-I Cells
Glutamatergic (VGLUT) and gamma-aminobutyric acid-ergic
(GABAergic; GAD65) phenotypes at D0, D3, and D7 were quanti-
fied to determine the impact of IGF-I on terminal differentiation.
GAD65-positive cells were significantly increased in the HK532-
IGF-I cell line compared with the parental HK532 cells, at 74%
and 67% of total cells, respectively (Fig. 4A, 4B, 4E). The percent-
ageof VGLUT-positive cells inHK532 (61%) andHK532-IGF-I (67%)
cultures were not significantly different (Fig. 4C, 4D, 4F). These
data demonstrate that IGF-I increases the number of GABAergic
neurons resulting from cell differentiation but has no significant
effect on the number of glutamatergic neurons.
HK532-IGF-I Are Resistant to Ab Toxicity and Protect
Primary CNs In Vitro
Ab(1-42) is a commonly used in vitromodel of AD-associated tox-
icity [57]. Significant apoptosis and CC3 activation was observed
in primary CNs and both NSC lines when exposed to Ab (Fig. 5A).
However, apoptosis levels in HK532 and HK532-IGF-I cells were
significantly lower than that observed in primary CNs (p ,
.001) (Fig. 5A), and HK532-IGF-I cells displayed increased resis-
tance to Ab toxicity compared with parental cells (p , .05)
(Fig. 5A). Furthermore, after 7 days of differentiation, both cells
lines displayed increased resistance to Ab toxicity; again, this
was significantly increased in HK532-IGF-I cells. Addition of
the IGF-IR inhibitor NVP reverted this increased resistance of
HK532-IGF-I cells back to levels of parental cells, indicating that
IGF-I production contributes to this enhanced resistance (Fig.
5A). To examine the protective capacity of the modified NSCs,
Ab toxicity was also assessed in primary CNs indirectly cocultured
with HK532 and HK532-IGF-I cells (Fig. 5B–5E). When quantified,
apoptosis in CNs, again indicated by CC3 activation, was signifi-
cantly decreased to below 40%when coculturedwith HK532 cells
and to below 30%, when cocultured with HK532-IGF-I cells (p,
.05) (Fig. 5H). These data indicate the HK532-IGF-I cell line is neu-
roprotective and prevents Ab-induced CN death by a paracrine
mechanism. Moreover, NVP reversed the additive neuroprotec-
tion conferred by HK-532-IGF‐I to that of parental HK532 (Fig.
5F–5H), thus indicative of a significant contribution of IGF‐I to
HK532-IGF-I neuroprotection.
HK532-IGF-I Survive Transplantation and Incorporate In
Vivo in an AD Mouse Model
We next transplanted HK532-IGF-I cells into APP/PS1 double-
transgenic mice, a commonly used model of AD [10, 58–64],
to establish the feasibility of preclinical testing. This pilot study
enabled optimization of targeting the fimbria fornix of the hip-
pocampus and assessment of transplanted cell survival over
time. Targeting accuracy was achieved in all animals injected.
Transplanted human cells were detected by IHC for HuNu
and DCX at 2 weeks (data not shown) and at 10 weeks post-
transplantation (Fig. 6). Grafted cells were evident in the hip-
pocampal regions of both AD (Fig. 6A–6F) and WT animals
(Fig. 6G–6L). Costaining of HuNu with DCX, which labels neuro-
nal precursors and is indicative of neurogenesis, suggested that
transplanted cortical NSCs were in an early neuronal differen-
tiation phase.
Figure 4. Terminal phenotype of HK532 and HK532-IGF-I cells. (A, B): Representative immunocytochemistry (ICC) images of D7 HK532 and
HK532-IGF-I cells labeled with 49,6-diamidino-2-phenylindole (DAPI) (blue) and GAD65 (green). (C, D): Representative ICC image of D7 cells
labeled with DAPI (blue) and VGLUT (red). (E): Quantification of GAD65-positive gamma-aminobutyric acid (GABA)ergic neurons in HK532
and HK532-IGF-I cells. HK532-IGF-I cells preferentially differentiate into GABAergic neurons (p, p , .05 vs. HK532). (F): Quantification of
VGLUT-positive glutamatergic neurons in HK532 and HK532-IGF-I cells. Data are presented as representative images or mean + SD of at least
three independent experiments. Scale bar = 200 mm. Abbreviations: D7, day 7; GAD, glutamic acid decarboxylase; VGLUT, vesicular glutamate
transporter.
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Figure 5. HK532-IGF-I cells are neuroprotective in vitro. (A):Quantification of apoptosis and cleaved caspase-3 (CC3) activation in response to
Ab toxicity in primary CNs and undifferentiated and differentiated (D7) HK532 and HK532-IGF-I cells. Both HK532 cell lines weremore resistant
thanCNs, andHK532-IGF-I cells displayed significantly increased resistance,whichwasnegatedwhen insulin-like growth factor-I (IGF-I) signaling
is blocked by addition of NVP. (B–G):Representative immunocytochemistry images of primary CNs labeledwithDAPI andCC3,where conditions
included (B) control CNswith no Ab treatment, (C) CNswith Ab treatment, (D) CNswith Ab treatment cocultured with HK532 cells, (E) CNswith
Ab treatment coculturedwithHK532-IGF-I cells, (F)CNswithAb treatment coculturedwithHK532 cells plusNVP, and (G)CNswithAb treatment
cocultured with HK532-IGF-I cells plus NVP. (H): Quantification of Ab-mediated apoptosis and CC3 activation in CN/HK532 cocultures. HK532-
IGF-I cells exhibited an increased neuroprotective capacity (p, p, .05 vs. HK532), which was reversedwith addition of NVP. Data are presented
asmean + SD or representative images of at least three independent experiments. Scale bar = 200mm. p, p, .05; pp, p, .0005. Abbreviations:
Ab, amyloid b; CC3, cleaved caspase-3; CN, cortical neuron; NVP, NVPAEW541.
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DISCUSSION
There is no cure for AD and nomeans of prevention. Currently ap-
proved drug treatments temporarily slow dementia symptoms
but ultimately fail to alter the disease course. Despite multitudes
of prospective compounds moving through the AD drug devel-
opment pipeline, little progress has been made and no new
treatments have been approved for AD since 2003 [65]. Given
the prevalence of AD and an increasingly aging population, we
urgently need to identify new therapeutic strategies. We con-
tend that a breakthrough disease modifying treatment for
AD must address complex underlying disease pathologies as
well as delay or even prevent neuronal damage and synaptic
degeneration.
NSC transplantation represents an exciting new approach to
treat AD. NSCs have a long-term self-renewal capacity, the poten-
tial to differentiate into a number of neural cell types, and the
ability to provide an unlimited source of cells for regenerative
medicine applications. Transplantation of NSCs improves brain
or motor functions after stroke, Parkinson’s disease, and amyo-
trophic lateral sclerosis (ALS) [66–68].We have previously shown
thathuman spinalNSCsdevelopneuronalmorphologies and form
synapses with host neurons in the spinal cord of ALS rats [67].
Furthermore, transplanted stem cells were able to modulate in-
flammation and significantly reduced astroglial and microglial
activation [67]. In AD, cell therapies also have the potential to
modify thedisease environment bymultiplemechanisms, confer-
ring a distinct advantage over single-target drug therapies. Cell
transplantation also carries the unique advantage of allowing sus-
taineddelivery of peptides or largemolecules,without needing to
contend with the blood-brain barrier and avoiding systemic side
effects. In fact, recent reports indicate that human central ner-
vous system-derived NSCs improve cognition in murine AD mod-
els [69, 70], further validating our approach and emphasizing the
need to identify the most effective cell type that will provide the
most clinical benefit to patients with AD.
In the present study,weengineered ahuman cortical NSC line
to produce increased levels of IGF-I to establish an enhanced and
multifaceted cellular therapy for AD. IGF-I is a potent neurotro-
phic factor that promotes neurogenesis and synaptogenesis
and also exerts antiapoptotic and anti-inflammatory effects
[30, 31, 38–45]. Given the neuroprotective potential of IGF-I,
we hypothesized that an enhanced human NSC line would prove
advantageous by providing cell-mediated protection as well as
further enriching the diseased environment. In AD, this poten-
tially includes the formation of synaptic contacts with host neu-
rons, modulation of inflammation, and the provision of general
neurotrophic support in the brain milieu, in addition to the ben-
efits of IGF-I production, synergistically blocking cell and synapse
loss.
Here, we investigated the characteristics and therapeutic
potential of an enhanced NSC line, HK532-IGF-I. These cells
exhibited a 50-fold increase in IGF-I expression with robust ex-
pression maintained throughout early differentiation, consistent
with results seen in our previous studies and those of others using
a similar approach [42, 71, 72]. Both parental HK532 and HK532-
IGF-I cells exhibited normal IGF-IR activation and MAPK/Akt
signaling profiles; however, we did observe a diminished respon-
siveness to exogenous IGF-I stimulation in HK532-IGF-I cells at
both time points examined. This is not unexpected, because
HK532-IGF-I cells displayed decreased levels of IGF-IR relative
to parental HK532 cells. It is also well documented that continu-
ous IGF-I stimulation results in IGF-I insensitivity, decreased re-
ceptor expression, and desensitization of IGF-IR [41, 42]. In line
with our previous studies in spinal NSCs, we also see increased
IGF-IR expression and signaling after differentiation in both cell
lines [42]. HK532 cells produce a number of growth factors,
including BDNF, GDNF, and VEGF. The cell secretome remains
largely unchanged inmodifiedHK532-IGF-I cells relative to paren-
tal cells, with the exception of VEGF, significantly increased levels
ofwhichwere detected in undifferentiated cells. Such an increase
in VEGF secretion may, in fact, augment the neuroprotective im-
pact of HK532-IGF-I cells in vivo. Several studies report beneficial
neurotrophic effects of cell-mediated VEGF production in AD,
which include reducing senile plaques, preventing AD-associated
excitotoxicity by decreasing acetylcholinesterase expression and
activity (a similar mechanism to AD drug treatments), and provid-
ing cognitive benefit in vivo [17, 73].
IGF-I impacts multiple cellular behaviors, including prolifera-
tion, migration, and differentiation [29–32]. Bearing in mind our
goal to develop HK532-IGF-I into a cellular therapy for use in pa-
tients, we next confirmed that that autocrine production of IGF-I
does not adversely impact cell behavior. No significant differ-
ences were found in HK532-IGF-I cell proliferation relative to pa-
rental cells at any timepoint.Wealso verified that enhanced IGF-I
expression does not influence the migratory capacity of HK532-
IGF-I cells. These findings are perhaps attributable to the reduced
expression of IGF-IR observed in HK532-IGF-I relative to HK532,
and indicate that IGF-I does not act as a mitogen for HK532 cells.
These data are similar to our previous studies assessing exoge-
nous IGF-I addition or induced IGF-I expression in human spinal
NSCs [41, 42], and demonstrate that combining IGF-I with
HK532 cells does not promote undesirable propagation. Together,
these data form a preliminary safety profile for HK532-IGF-I
cells, which will be confirmed by rigorous in vivo tumorigene-
sis studies, as required by the FDA for further preclinical
development.
Interestingly, IGF-I modification did not significantly affect
the amount of differentiation observed between cell lines. Our
previous work on spinal NSCs demonstrated an increase in differ-
entiation with IGF-I [41], suggesting that the effects of IGF-I on
neural progenitor differentiation is cell-line specific.Wedid, how-
ever, observe a significant change in the terminal phenotype,
where HK532-IGF-I cells yielded significantly increased numbers
of GAD65-positive GABAergic neurons. This is therapeutically rel-
evant because diminished function of GABAergic neurons is re-
ported in mouse models and human patients [74, 75]. Thus, an
interesting idea to pursue iswhether HK532-IGF-I transplantation
may provide a source of de novo GABAergic neurons to replace
those dysregulated in AD and restore critical neurocircuitry in
the brain.
The neuroprotective capacity of IGF-I and its ability to pre-
vent apoptosis has been shown in multiple neural cell types, in-
cluding cortical, motor, and sensory neurons, when subjected to
a wide range of stressors [30, 33, 45, 76–79]. Exogenous IGF-I
also improves transplant microenvironments and promotes
transplanted cell survival under different pathological condi-
tions in vivo, including spinal cord injury [78, 80]. To assess
the therapeutic impact of HK532-IGF-I, we first examined the
susceptibility of our enhanced IGF-I cell line to the AD microen-
vironment by treating cells with Ab, which is neurotoxic to neu-
ronal cell lines in vitro [81, 82]. We found significantly reduced
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levels of cell death in both undifferentiated and differentiated
HK532-IGF-I cells compared with that observed in primary
CNs. These data indicate that these cortical NSCs display an
increased resistance to AD-related toxicity, supporting their
ability to survive following intracranial transplantation, and
offer a healthy, more resistant cellular population in the AD
brain. We also demonstrated reduced apoptosis of CNs when
they are indirectly cocultured with HK532-IGF-I cells. Impor-
tantly, this enhanced protection is attributed to increased
levels of IGF-I, as evidenced by an increased protective capac-
ity of HK532-IGF-I cells relative to HK532 cells and reversal of
this effect when IGF-I signaling is inhibited. This is supported
by our previous findings demonstrating that IGF-I expression
increased resistance of spinal cord NSCs to cellular insults
[41, 42]. Together, these data indicate that IGF-I will provide
enhanced protection in AD, advocating the potential thera-
peutic efficacy of HK532-IGF-I. Furthermore, in the context
of the hippocampus, we predict that in addition to preventing
cell death, HK532-IGF-I will promote neurogenesis and synap-
togenesis in the hippocampus via IGF-I-mediated signaling
[40, 83], which will be addressed in our future preclinical
studies.
Finally, we tested the feasibility of HK532-IGF-I transplanta-
tion into the AD brain using the APP/PS1 transgenic mouse.
APP/PS1 mice have been used extensively as a preclinical model
of AD [58–64]. Here, we report successful cellular transplantation
into the murine fimbria fornix, a major projection pathway con-
necting the hippocampus to cortical and subcortical brain struc-
tures. Targeting this area for cell transplantation will provide a de
novo tissue source as well as trophic support, and, importantly,
impacting this target area has the potential to rescue memory
and learning deficits in AD. Our preliminary data demonstrate
successful targeting of HK532-IGF-I cells into the fimbria fornix
of thehippocampus in theADbrain.Graftsweredetected2weeks
and10weeksposttransplantationbyHuNu staining, verifying sur-
vival of human cells in the AD brain for a clinically relevant period
of time. We saw no difference in cell graft size between WT and
AD animals. In addition, HuNu-positive cells expressed DCX, a
marker of neurogenesis. DCX expression is specific to newly gen-
erated healthy neurons [84], and indicated that the transplanted
cells were differentiating into neural cell types in vivo. Together,
these data provide a platform for future, large-scale, preclinical
studies in murine models of AD to assess the therapeutic benefit
of cellular therapy inmodifying deficits in behavior, memory, and
learning.
CONCLUSION
NSC transplantation offers a novel and potentially transformative
approach to treating neurodegenerative disease. The safety of
such cell therapies is now established in several clinical trials, in-
cluding our own trial in patients with ALS [85–87]. To progress to
similar trials in patients with AD, it is critical that NSC lines provid-
ing the greatest efficacy be identified; this prompted us to gener-
ate the enhancedNSC line, HK532-IGF-I.We report that autocrine
IGF-I production does not impact normal cellular functions, in-
cluding proliferation, migration, or maintenance of progenitor
status, thusmaintaining thepotential safetyprofile of this cell line
for future clinical application. HK532-IGF-I cells display a signifi-
cantly enhanced neuroprotective capacity in vitro and survive
long term in vivo after transplantation into the murine AD brain,
Figure 6. HK532-IGF-I cells survive grafting into APP/PS1 mice with
Alzheimer’s disease (AD) and wild-type (WT) mice. Representative
images of HK532-IGF-I cells in the hippocampal area of APP/PS1 AD
(A–F) and WT (G–L) mice 10 weeks following transplantation to the
fimbria fornix. H&E staining shows the transplanted target area
(square) in AD (A) and WT (G) mice. Immunofluorescent DAPI,
HuNu, andDCX labeling of human early neural precursor cells in the hippo-
campal area of AD (B–F) andWT animals (H–L). Data are presented as
representative images (A–F: APP/PS1, n = 4; G–L: WT, n = 4). (A, G):
Scale bar = 200mm. (B, H):310 scale bar = 200mm. (C–F, I–L):360 scale
bar = 50 mm. Abbreviations: DAPI, 49,6-diamidino-2-phenylindole; DCX,
Doublecortin; H&E, hematoxylin and eosin; HuNu, human nuclei.
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confirming the feasibility of our approach. We predict that in AD,
HK532-IGF-I cells will provide additional environmental enrich-
ment through IGF-I production, secondary to beneficial effects
on synaptogenesis and inflammation, as observed in the spinal
cord of ALS models. Additionally, HK532-IGF-I cells preferen-
tially differentiate into GABAergic neurons, a population selec-
tively lost in AD, and produce increased levels of VEGF, further
validating this cell line as a suitable candidate for cell transplan-
tation. Future, large-scale small-animal studies are necessary
to establish preclinical efficacy in models of AD. Overall, our
findings support further development of IGF-I-producing NSCs
as a safe and clinically translatable cellular therapy for patients
with AD.
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